US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment
The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Yahoo3d
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment
(Reuters) -The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood disorder treatment Soliris. Amgen's drug will be marketed under ...
Managed Healthcare Executive13h
FDA Updates for Week of May 27: 2 Approvals including New Biosimilar
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi for mantel cell lymphoma. The agency has delay a decision on Dupixent in ...
Should you buy Amgen’s stock above $300?
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
KELO3d
US FDA approves Amgen’s biosimilar to AstraZeneca’s rare blood disorder treatment
(Reuters) -The U.S. Food and Drug Administration approved on Tuesday Amgen’s Bkemv, the first biosimilar to AstraZeneca’s rare blood disorder treatment Soliris. Amgen’s drug will be marketed under the ...
headtopics11d
FDA Approves New Drug for Deadly Lung Cancer
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. The U.S. Food and Drug Administration on Thursday approved a new ...
clinicalpainadvisor.com9d
FDA Approves New Drug for Deadly Lung Cancer
Tarlatamab arrives after decades of no real treatment advances for this type of lung cancer. HealthDay News — The U.S. Food and Drug Administration on Thursday approved a new drug to treat ...